Heartwave II
This article was originally published in The Gray Sheet
Executive Summary
FDA clears Cambridge Heart's third-generation Microvolt T-wave Alternans sudden cardiac death risk diagnostic system, the firm says April 11. Unlike previous versions of the system, Heartwave II can complete all of the elements of a MTWA test and does not require a host stress exercise system to control the treadmill during the stress-test portion of the diagnostic procedure. Medtronic is co-sponsoring an MTWA registry to help determine whether the test can identify post-MI heart failure patients most likely to benefit from an implantable cardioverter defibrillator (1"The Gray Sheet" July 14, 2003, p. 32)...
You may also be interested in...
MTWA Testing Would Lead To More ICD Referrals – Medtronic
Medtronic is sponsoring a registry to help determine whether microvolt T-wave alternans (MTWA) testing can identify post-MI patients with a left-ventricular ejection fraction (LVEF) of 30%-40% who are most likely to benefit from an ICD
California Bill To Age-Restrict Sales Of Diet Pills Further Along Than Other States’ Legislation
CA, MA and NJ legislatures remain in session with bills active proposing regulations similar to NY law effective 22 April requiring retailers, including online, to ask for proof of age when customers buying consumer health products containing ingredients labeled or promoted for weight loss and bodybuilding benefits appear younger than 18.
CRN Has Standing For Steep Hill To Climb Challenging New York's Age-Restricted Sales
Federal judge finds “misreading of the legislation” in CRN’s argument that state “restricts access based purely on what has been said about the product or its ingredients.” But standing to challenge “means that only CRN is positioned right now to go before the court on behalf of industry,” says CEO Steve Mister.